Company Encyclopedia
View More
name
CMS
00867.HK
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn’s disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne.
1.390 T
00867.HKMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking4/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.02%B
    • Profit Margin21.00%A
    • Gross Margin72.26%A
  • Growth ScoreB
    • Revenue YoY12.23%B
    • Net Profit YoY18.90%B
    • Total Assets YoY6.28%B
    • Net Assets YoY9.47%B
  • Cash ScoreB
    • Cash Flow Margin476.20%C
    • OCF YoY12.23%B
  • Operating ScoreC
    • Turnover0.42C
  • Debt ScoreA
    • Gearing Ratio9.35%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | CMS steadily rebounds, can the pharmaceutical sector open a rebound window?

    CMS (867.HK) performed outstandingly on the 16th, with funds actively lifting the stock price in the early market, and the bullish atmosphere continued until the close. The stock price closed higher on the daily line, with recent trading volume expanding positively, and a local rebound chain emerging within the pharmaceutical sector. There are signs of tentative capital returning in batches, with increased follow-up buying. On the news front, the company's third-quarter earnings guidance continues to release positive signals. The commercialization progress of new drugs is smooth, leading to some capital spilling over into pharmaceutical growth stocks. Innovative drugs are under regulatory scrutiny, and the sector has recently received marginal policy benefits. The daily line has seen continuous volume expansion, and trading has become significantly active after breaking through the consolidation platform, with both 8-hour and 24-hour trends continuing to rise. The technical RSI indicator shows a short-term bias towards strength, and there may be fluctuations and repeated demand during the trading session. Overall, the pharmaceutical sector is still in a bottoming phase, and if the main capital continues to increase its control and volume, the rebound window is expected to open fully. In the short term, one should still guard against the pressure of a pullback after a rise and pay attention to whether the market can continue to attract incremental capital. The expansion of the market needs to rely on sustained volume and policy follow-up. Investors should focus on changes in capital inflow and flexibly grasp the rhythm of the rebound and volatility risks

    Technical Forecast·
    HK
    00867
    +0.38%
    Technical Forecast·
    HK
    00867
    +0.38%

    CMS monoclonal antibody injection "MG-K10" listing application accepted

    CMS announced that its subsidiary, Demy Pharmaceuticals, along with its affiliates, has obtained the joint development rights and exclusive commercialization rights for the Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (generic name: Kemeiqibai monoclonal antibody injection, "MG-K10"). The application for marketing authorization in China has been accepted by the National Medical Products Administration of China. "MG-K10" is intended for the treatment of moderate to severe atopic dermatitis in adults who have poor control with topical medications or for whom topical treatments are not suitable

    AASTOCKS·
    HK
    00867
    +0.38%
    AASTOCKS·
    HK
    00867
    +0.38%

    CMS signed a distribution agreement with Novartis for the ophthalmic drugs Nofluprednate® and Bevacizumab®

    CMS has signed a distribution agreement with Novartis to obtain exclusive import, distribution, sales, and promotion rights for Ranibizumab Injection (Lucentis®) and Brolucizumab Injection (Beovu®) in mainland China. The cooperation period is five years, with Novartis responsible for production and supply. This move will enhance CMS's competitiveness in the ophthalmology field, integrate market channels and academic resources, and is expected to have a positive impact on the group's performance

    Zhitong·
    HK
    00867
    +0.38%
    Zhitong·
    HK
    00867
    +0.38%

    CMS MG-K10 has been approved to conduct clinical trials for new indications

    CMS announced that its Class 1 new drug MG-K10 has been approved by the National Medical Products Administration of China to conduct clinical trials for chronic obstructive pulmonary disease. MG-K10 is a humanized monoclonal antibody injection that has achieved positive results in Phase III clinical studies for adult patients with severe atopic dermatitis, meeting the primary research endpoint

    AASTOCKS·
    HK
    00867
    +0.38%
    AASTOCKS·
    HK
    00867
    +0.38%

    CMS has obtained the clinical trial approval notice for the new indication of chronic obstructive pulmonary disease for the Class 1 new drug MG-K10 humanized monoclonal antibody injection

    CMS has received approval from the National Medical Products Administration (NMPA) of China to conduct clinical trials for the Class 1 new drug MG-K10 humanized monoclonal antibody injection in chronic obstructive pulmonary disease (COPD). The co-development rights and exclusive commercialization rights for the drug are owned by CMS, and the approval notice was issued on September 29, 2025

    Zhitong·
    HK
    00867
    +0.38%
    Zhitong·
    HK
    00867
    +0.38%
    © 2025 Longbridge｜Disclaimer